Aft Forsyth & Sober’s iShares Biotechnology ETF IBB Stock Holding History

Aft Forsyth & Sober’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-325	Closed	-$44K	–	44
2020 Q2	$44K	Buy	+325	New	+$41.4K	0.31%	38

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Aft Forsyth & Sober's IBB Position: Q3 2020 in Review

Aft Forsyth & Sober sold out of iShares Biotechnology ETF (IBB) in Q3 2020, closing a stake of 325 shares — an estimated $44K sold.

Aft Forsyth & Sober first reported a position in IBB in Q2 2020 and held it in 1 quarter. The position peaked at $44K in Q2 2020. 784 funds tracked by Wall St. Rank hold IBB as of Q3 2020.

Aft Forsyth & Sober reported no remaining iShares Biotechnology ETF position as of Q3 2020 after selling out during the quarter.
Aft Forsyth & Sober sold 325 iShares Biotechnology ETF shares in Q3 2020, an estimated $44K.
Aft Forsyth & Sober first reported a position in iShares Biotechnology ETF in Q2 2020 and held it in 1 quarter.
Aft Forsyth & Sober's iShares Biotechnology ETF position peaked at $44K in Q2 2020.
784 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2020.

Based on Aft Forsyth & Sober's 13F filing for Q3 2020, filed 14 Oct 2020.